Table 2 Number of cancer cases among subjects that subsequently became digitoxin users.
From: Digitoxin medication and cancer; case control and internal dose-response studies
ICD-10 | Site | Sex | Digitoxin group | Control group | Odds Ratio (95% CI) |
|---|---|---|---|---|---|
C50 | Breast | F | 275 | 232 | 1.19(1.11, 1.28) |
C61 | Prostate | M | 370 | 296 | 1.25(1.08, 1.45) |
C18–21 | Colo-rectal | M+F | 430 | 325 | 1.32(1.15, 1.52) |
C32–34 | Lung | M+F | 163 | 112 | 1.46(1.15, 1.86) |
C64,C65,C67,C68 | Kidney, urinary | M+F | 201 | 180 | 1.06(0.95, 1.17) |
C43.C44 | Melanoma, other skin | M+F | 154 | 191 | 0.81 (0.66, 0.99) |
C81–C85,C88– | Leukemia/Lymphoma | M+F | 198 | 117 | 1.69(1.35,2.11) |
C92 | |||||
C00–C97 | All sites | M+F | 2435 | 2017 | 1.21 (1.15, 1.28) |